NDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CORVERT (ibutilide fumarate) by Pfizer is mechanism of action: corvert injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo , ie, class iii electrophysiologic effects. First approved in 1995.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORVERT (ibutilide fumarate) is an intravenous class III antiarrhythmic agent approved in 1995 for acute conversion of atrial fibrillation and atrial flutter. It works by prolonging action potential duration and refractoriness through activation of a slow inward sodium current, a unique mechanism distinct from potassium channel blockers used by most other class III agents. It is administered as an injectable formulation for rapid rhythm restoration in acute care settings.
LOE Approaching
With LOE approaching and modest competitive pressure (30), the brand team is likely in defensive/transition mode with reduced headcount expectations.
Mechanism of Action
Mechanism of Action: CORVERT Injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo , ie, class III electrophysiologic effects. Voltage clamp studies indicate that CORVERT, at nanomolar concentrations, delays…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CORVERT offers limited career growth given its LOE approaching status and zero linked job openings; roles are primarily defensive, focused on compliance and market maintenance rather than expansion. Professionals joining this product should expect stable but non-growth career trajectories with eventual repositioning or exit as generic competition intensifies.
Worked on CORVERT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.